PT  - JOURNAL ARTICLE
AU  - Bhavin Vasavada
AU  - Hardik Patel
TI  - Post-operative day 3 Procalcitonin predicts post-operative infectious complications in pancreatic surgery – A systemic review and updated meta-analysis
AID  - 10.1101/2020.09.21.20198994
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.21.20198994
4099  - http://medrxiv.org/content/early/2020/09/23/2020.09.21.20198994.short
4100  - http://medrxiv.org/content/early/2020/09/23/2020.09.21.20198994.full
AB  - Aim of study Aim of this meta-analysis is to evaluate post-operative procalcitonin as a marker to predict post-operative infectious complications after pancreatic surgeries.Material and Methods Systemic literature search was performed using MEDLINE, EMBASE and to identify studies evaluating the diagnostic accuracy of Procalcitonin (PCT) as a predictor for detecting infectious complications on postoperative days (POD) 3 and 5 following pancreatic surgery. A meta-analysis was performed using random effect model and pooled predictive parameters for POD 3 and 5 were derived. Geometric means were calculated for PCT cut offs.Results 6 studies included day 3 PCT analysis, 2 studies included both day 3 and day 5 analysis. Total data of 471 patients were derived. 161 patients developed infectious complications. Pooled sensitivity, specificity, pooled area under curve, diagnostic odds ratio (DOR), positive and negative like hood ratio of day 3 PCT were 74%,79%,0.8453, 11.03,3.17 and 0.31 respectively. Pooled sensitivity, specificity, diagnostic odds ratio (DOR), positive and negative like hood ratio of day 5 PCT were 83%,70%,12.91,2.91 and 0.25 respectively. Geometric means for PCT cut off for day 3 and 5 were 0.80 and 0.43.Conclusion Postoperative procalcitonin particularly day 3 procalcitonin levels predict post-operative infectious complications following pancreatic surgeries.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno funding availableAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Shalby hospitalsAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata will be made available on demand